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Background: Overexpression of c-kit, a tyrosine kinase receptor
protein encoded by the protooncogene kit, has been previously
reported in thymic epithelial tumors and in other neoplasms such as
gastrointestinal stromal tumors, myeloproliferative disorders, mela-
noma, and seminoma. Mutations in the kit gene have been related to
response to imatinib in gastrointestinal stromal tumor and one case
report of thymic carcinoma. We studied expression of c-kit in a large
retrospective series of thymic epithelial malignancies and sequenced
the whole gene in a subset of patients.
Methods: Thymic epithelial tumors from 120 patients (13 thymic
carcinomas and 107 thymomas) were examined. Immunohistochem-
ical staining with an antic-kit polyclonal antibody was performed on
a tissue microarray. Mutation analyses of exons 1 to 20 were
conducted by direct DNA sequencing of polymerase chain reaction
products in eight thymic carcinomas, five thymomas, and one
thymic carcinoma cell line.
Results: The percentage of c-kit positive cells was significantly
higher in thymic carcinoma (46%) than in thymoma (4%). De-
creased disease-related survival and progression-free survival were
observed in c-kit positive tumors. No mutations were detected.
Conclusion: c-kit expression is strongly but not exclusively related
to thymic carcinoma histotype, and it is of prognostic value. Muta-
tions are very rare.
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Thymic malignancies are rare tumors with an overall inci-dence of 0.15 each 100,000 persons-year; however, they
are the most common anterior mediastinal neoplasm in
adults, representing 50% of anterior mediastinal masses.1,2
The 2004 World Health Organization (WHO) classification
recognizes five histologic subtypes of thymoma (A, AB, B1,
B2, and B3) and 11 subtypes of thymic carcinomas.3 Surgery
is the mainstay treatments for localized tumors. However,
thymic carcinomas and less frequently thymomas display an
aggressive behavior that requires combined modality treat-
ments, including systemic therapy. Many patients with met-
astatic or unresectable tumors are candidates for systemic
platinum-based chemotherapy, which is palliative in nature.
Development of new drugs is important in thymic malignan-
cies but is hampered by the rarity of this disease. Several
molecularly targeted therapies have recently been investi-
gated in thymic malignancies, but results of phase II studies
have so far been disappointing.4
c-kit is a type III cytokine receptor expressed on the
membrane of hematopoietic stem cells, mast cells, melano-
cytes, and interstitial cells of Cajal.5 Stem cell factor binds to
c-kit inducing homodimerization of the receptor and phos-
phorylation of downstream intracellular molecules that regu-
late cell proliferation, differentiation, adhesion, and apopto-
sis.6 Overexpression of c-kit is observed in a spectrum of
human malignancies, primarily gastrointestinal stromal tu-
mors (GISTs), chronic myeloid leukemias, mast cell neo-
plasms, melanomas, and seminomas.7 c-kit mutations have
also been described in several of these tumors.6,8 In GISTs,
the most common mutations affect exons 11, 9, 13, and 17,6
and the site of mutation has prognostic implications in this
disease. Responsiveness of GISTs to treatment with the
kinase inhibitor imatinib depends largely on the exonic loca-
tion of the c-kit mutation.6 Higher objective response rates to
imatinib have been described in patients with mutations of
exon 11 compared with patients with wild-type receptor or
with mutations of exon 9.9 Mutations have been also de-
scribed in patients with negative c-kit expression, evaluated
by immunohistochemistry (IHC).10 Durable responses to ima-
tinib treatment were observed in GIST patients with a very
low expression of c-kit but showing exon 11 mutation.11
In thymic epithelial tumors, c-kit expression has been
reported between 50% and 88% in thymic carcinoma, but it is
rare in thymomas (0–5%).7,12–16 In thymic carcinoma, five
mutations have been described in total in the literature.7,15–17
Recently, Girard et al.14 reported two c-kit mutations, of
seven thymic carcinomas analyzed. One of these mutations
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(H697Y) was novel and in exon 14, a region not sequenced in
previous studies.
In 2004, Strobel et al.17 reported a case of poorly
differentiated epidermoid carcinoma with V560del kit muta-
tion who responded to imatinib. In 2009, another case of
thymic carcinoma with D820E kit mutation was reported that
responded to sorafenib, a multitargeted tyrosine kinase inhib-
itor, with weak c-kit inhibitory activity.18,19 Two phase II
studies have been performed with imatinib in patients with
mainly thymic carcinoma.20,21 There were, however, no re-
sponses in these two studies that enrolled a total of 16 patients
with thymic carcinoma. Unfortunately, only three patients
were sequenced for c-kit mutations and found to have wild-
type c-kit.20
The objectives of this study were to investigate kit
mutation status, to extend sequencing to exons not previously
evaluated in thymic epithelial malignancy (TEM), and to
define the relationship between protein expression, assessed
by immunohistochemistry, and prognosis.
We evaluated the c-kit expression in a series of 120
thymic epithelial tumors and confirmed a higher percentage
of c-kit positive cells in thymic carcinomas (46%) than
thymomas (4%). We also identified a statistically significant
correlation between c-kit expression and poorer disease-re-
lated survival (DRS) and progression-free survival (PFS). We
sequenced kit gene from exons 1 to 20 of eight formalin-fixed
paraffin-embedded (FFPE) thymic carcinoma samples, one
thymic carcinoma cell line, and five FFPE thymoma samples.
No mutations were identified.
PATIENTS AND METHODS
Patient Samples
FFPE specimens were retrieved from the pathology
department of the Istituto Clinico Humanitas (Rozzano,
Milan, Italy). Consecutive cases with a diagnosis of thy-
moma or thymic carcinoma with available tumor tissue
were selected. Tumors were reviewed and classified ac-
cording to the 2004 WHO criteria.22 Tumor staging was
according to the revised Masaoka system.23 Main patient
characteristics are reported in Table 2. The completeness
of resection was classified as R0  complete resection,
R1  microscopic residual disease infiltrating resection
margins, and R2  macroscopic residual disease.24 This
study was conducted in agreement with the Declaration of
Helsinki and was approved by the institutional ethical
review boards (ClinicalTrials.gov ID: NCT00965627).
Construction of Tissue Microarray
FFPE tumor specimens were assessed for quality and
adequacy of fixation and storage. A tissue microarray block
containing tissue from 132 thymoma or thymic carcinoma
cases was generated. In brief, three punches of 0.36 mm2 (0.6
mm in diameter) were taken from different intratumoral areas
in each tumor sample and arranged in the recipient tissue
array block. For 21 samples, peritumoral normal tissue was
also available and included in the tissue microarray. A pa-
thologist (H.S.L.) verified the presence of tumor tissue on a
hematoxylin and eosin-stained tissue microarray slide. Sam-
ples were considered adequate if tumor occupied one or more
cores of three punches.
Immunohistochemistry
Expression of c-kit was analyzed by IHC. FFPE tissue
microarrays were cut at 4 m, deparaffinized with xylene,
and rehydrated in graded ethanol. Antigen retrieval was
performed heating the slides at 95°C for 20 minutes in Target
Retrieval Solution (Dako, Carpinteria, CA). Endogenous per-
oxidase blocking solution (EnVision System HRP [DAB],
Dako) was applied on the tissue for 10 minutes followed by
incubation in protein-free T20 (TBS) blocking buffer
(Thermo Scientific, Rockford, IL) for 1 hour. Samples were
then incubated with c-kit pharmDx Polyclonal Rabbit IgG
(c-kit pharmDx IHC kit, Dako) for 30 minutes in a humid
chamber at room temperature. After three washes with Tris-
Buffer saline Twin 20 0.5% buffer, the slides were incubated
for 30 minutes with labeled polymer-HRP as a secondary
antibody and then immune reactions were visualized with
3,3-diaminobenzidine as chromogen (EnVision System
HRP [DAB], Dako). Slides were counterstained with hema-
toxylin, dehydrated, and mounted. Negative control speci-
mens were included with Rabbit IgG Negative Control Re-
agent (c-kit pharmDx IHC kit, Dako). As positive controls,
specimens of FFPE P815 mouse mastocytoma cell line (c-kit
pharmDx IHC kit, Dako) and mouse normal pancreas were
used, according to the vendor’s instructions. Degree of im-
munostaining was scored as follows by one pathologist
(H.S.L.) who was blinded to the patients’ information: , no
staining; 1, staining 10% of tumor cells; 2, staining
10% but 50% of tumor cells; or 3, staining 50% of
tumor cells.13,16 Positive were considered samples with at
least 1.
Cell Line
Thymic carcinoma cell line T1889 was kindly provided
by Marco Breinig.25 The cells were cultured in RPMI 1640
containing 25 mM Hepes, 200 mM L-glutamine (Gibco,
Invitrogen, Grand Island, NY), 50 U/ml penicillin, 50 U/ml
streptomycin (Invitrogen), and 10% heat-inactivated calf se-
rum (Invitrogen), and grown in a 37°C incubator with hu-
midified 5% CO2 atm.
Genomic DNA Sequencing
A hematoxylin and eosin-stained slide was obtained for
each sample. A pathologist verified the presence of tumor
tissue, marking the areas with more than 80% cancer cells on
the paraffin blocks. Five cores of tissue were punched from
the marked area on FFPE blocks using a 0.6 mm tissue
microarray needle by a depth of approximately 1 mm. DNA
was extracted using DNeasy kit (Qiagen Inc., Valencia, CA).
Samples were sequenced as described previously.26 Briefly,
coding sequences were amplified by polymerase chain reac-
tion (PCR) using AmpliTaq Gold PCR Master Mix (Applied
Biosystems, Foster City, CA). Primers tagged with M13
sequence were used to sequence exons 1 to 20. The sequences
of the primers are listed in Table 1. A total of 40 cycles were
performed using Veriti 96-Well Thermal Cycler (Applied
Biosystems) at 94°C for 30 seconds, 60°C for 45 seconds,
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and 72°C for 45 seconds. Polymerase chain reaction products
underwent ExoSAP-IT (USB, Cleveland, OH) purification.
The purified product was directly sequenced using a BigDye
terminator v 3.1 cycle sequencing kit (Applied Biosystems)
and 3730xl DNA Analyzer (Applied Biosystems). Data were
analyzed using Mutation Surveyor v 3.23 (SoftGenetics LLC,
State College, PA).
Statistical Analysis
Clinical and biologic features were compared using the
Fisher’s exact test or 2 tests, when appropriate. Survival
curves were generated using the Kaplan-Meier method, and
differences between curves were analyzed using the Log-
Rank and Breslow test. DRS was calculated from the date of
surgery to the death date. Patients alive or dead for causes
other than thymoma were censored. PFS was calculated from
the date of surgery to date of progression assessed according
to RECIST criteria. Patients without evidence of progression
were censored. All tests were performed using SPSS version
17 (SPSS Inc., Chicago, IL).
RESULTS
c-kit IHC
Patient characteristics of results of c-kit expression and
grading are reported in Table 2. Examples of positive and
negative samples are shown in Figures 1A, B. There was no
c-kit expression by IHC in the normal residual thymus of nine
evaluable patients. Ten (8.3%) of 120 evaluable samples were
positive for c-kit expression. This included 6 of 13 thymic
carcinomas tested (46%) and 4 of 107 thymomas (4%). c-kit
expression was significantly more frequent in thymic carci-
noma than in thymoma (Fisher’s exact test, p  0.0001).
There was no difference in c-kit expression between early
versus advanced stages, level of completeness of resection,
and primary versus relapsed tumors. However, c-kit-positive
samples were all found in primary tumors (98 cases) and none
in relapsed tumors (22 cases). All patients with tumors
showing c-kit expression were older than the median age of
55 years (Fisher’s exact test, p  0.001).
c-kit expression was associated with a worse DRS
(Log-Rank, p  0.028 and Breslow, p  0.002). The 10-year
DRS was 90% for c-kit-negative patients and 71% for c-kit-
positive patients (Figure 1C). A statistically significant worse
PFS was observed using the Breslow test (p  0.001) but not
using the Log-Rank test (p  0.061). The 10-year PFS was
70% for c-kit-negative patients and 50% for c-kit-positive
patients (Figure 1D).
Patients with thymic carcinoma showed a statistically
significant worse DRS than thymomas (Log-Rank, p  0.002
and Breslow, p  0.003). Median survival was not reached for
both groups. The 10-year DRS was 60% for thymic carcinomas
and 91% for thymomas (Figure 1E). Also, the PFS was signif-
icantly worse for thymic carcinomas (Log-Rank, p 0.021 and
Breslow, p  0.002). The estimated median PFS was 69.4
months for thymic carcinoma (confidence interval: 0–142.7)
and 147 months for thymomas (confidence interval: 121.7–
172.4). The 10-year PFS was 43% for thymic carcinoma and
72% for thymomas (Figure 1F). By multivariate analysis, c-kit
expression and the difference between thymic carcinoma and
thymoma were neither independent prognostic factors for DRS
(p 0.67 and 0.22, respectively) nor for PFS (p 0.79 and p
0.23, respectively).
kit Sequencing
We sequenced kit in eight thymic carcinomas and
five thymomas from FFPE samples with a success rate of
TABLE 1. Primers Used for Polymerase Chain Reactions
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77.5%. Histologic characteristics of the tumors that under-
went sequencing are reported in Table 3. We did not detect
mutations in any of the tumor samples and in the T1889
thymic carcinoma cell line, previously reported to be
negative for c-kit expression.25 We observed the previ-
ously reported single-nucleotide polymorphism corre-
sponding to M541L in one type A thymoma and in one
thymic carcinoma.
DISCUSSION
In our study of 120 patients with thymic malignancies,
we confirmed a significantly higher incidence of c-kit-posi-
tive cells in thymic carcinoma compared with thymoma. This
is one of the largest series reporting on expression of c-kit in
TEM. We observed c-kit expression in 46% of thymic carci-
nomas and in 4% of thymomas. The low expression in
thymomas is in line with previous reports where expression
ranged between 0% and 5%.7,12,13,15,16 Overall, considering
all cases reported in the literature, only 7 of 366 thymomas
analyzed resulted positive for c-kit expression (2%) (Table 4).
c-kit expression in thymic carcinomas has been reported to
range between 50% and 88%.7,12,13,15,16 Overall, 95 of 127
(75%) thymic carcinomas resulted positive for c-kit expres-
sion.7,12–18,20,21,27 Thymic epithelial cells are considered the
cells of origin for both thymoma and thymic carcinoma, and
normal thymic epithelium does not express c-kit.28 Our study
confirmed the lack of c-kit expression in residual normal
thymus of nine thymoma patients.
The variability of c-kit expression in thymic carcinomas
may be related to the small number of cases analyzed in
single studies, ranging between 6 and 22. Although most of
the studies used the same antibody that we also used, not all
studies considered only membranous staining as positive,
which may have resulted in the higher percentage of positiv-
ity. Moreover, these results also underline the histologic
heterogeneity of the thymic carcinoma group for which the
2004 WHO classification describes 11 subtypes.22 c-kit ex-
pression seems to be frequent in squamous cell thymic
carcinoma in all published reports. However, expression has
been described in other subtypes as well, including lympho-
epithelioma-like,12 undifferentiated carcinomas,12 and
basaloid carcinoma.13 In our study, one of two mucinous
adenocarcinomas stained strongly positive.
For the first time, we report a worse DRS and PFS for
patients with c-kit expressing tumors. These data suggest a
negative prognostic role for c-kit expression especially within
the first 3 years (Figure 1D). c-kit expression has also been
reported as a poor prognostic factor in small cell lung can-
cer.29,30 We used DRS and PFS as prognostic endpoint rather
than overall survival because of the long expected survival
after radical surgery. The median DRS was not reached for
patients with either c-kit-positive or negative tumors.
However, by multivariate analysis, c-kit expression was
not an independent prognostic factor for TEM histotype in
our study.
The 10-year DRS (60%) that we observed in thymic
carcinoma differs from previously reported overall survival
(around 40%) in a similar surgical series.32 However, in our
study, we assessed DRS and not overall survival, which in a
relatively indolent disease may not be accurate. Moreover, in
the study by Chen et al.31 thymic carcinomas were diagnosed
in higher stages of the disease compared with our series (83%
versus 69% stages III and IV, respectively).
We did not observe any c-kit positive tumors in patients
who underwent surgery for relapse. Although c-kit expression
is strongly related to thymic carcinoma histology, even if the
relapse rate is high in thymic carcinoma, these tumors are
TABLE 2. Patient Characteristics and c-kit
Immunohistochemistry
Samples c-kit  (%) 1 2 3
Age (y)
55 58 0 0 0 0
55 62 10 (16) 4 2 4
Sex
M 60 5 (8.3) 1 2 2
F 60 5 (8.3) 3 0 2
Tumor sample
Primary 98 10 (10) 4 2 4
Relapse 22 0 0 0 0
WHO
A 12 2 (17) 2 0 0
AB 24 1 (4) 1 0 0
B1 24 0 0 0 0
B1/B2 6 0 0 0 0
B2 7 0 0 0 0
B2/B3 10 0 0 0 0
B3 22 1 (5) 0 0 1
C 13 6 (46) 1 2 3
Othera 2 0 0 0 0
Subtotal
Thymoma 107 4 (4) 3 0 1
Carcinoma 13 6 (46) 1 2 3
Stage
I 29 4 (14) 2 1 1
IIa 26 0 0 0 0
IIb 17 1 (6) 1 0 0
IIIa 12 3 (25) 1 1 1
IIIb 3 0 0 0 0
Iva 5 0 0 0 0
IVb 10 2 (20) 0 0 2
Nab 18 0 0 0 0
Resection
R0 69 7 (10) 3 2 2
R1 22 2 (9) 1 0 1
R2 9 1 (11) 0 0 1
Na 20 0 0 0 0
Paraneoplasticc
Yes 30 1 (3) 1 0 0
No 84 8 (10) 3 2 3
Na 6 1 (17) 0 0 1
a One micronodular and one cystic thymoma.
b Na, not assessable: data are missing at the diagnosis.
c Paraneoplastic, paraneoplastic syndromes: 29 myasthenia gravis cases and one
autoimmune glomerulonephritis.
WHO, World Health Organization.
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mostly not resectable due to their more aggressive and infil-
trative behavior. If fact, no thymic carcinoma was resected on
relapse, in our series.
Only a few c-kit mutations have been reported in the
literature in TEM and exclusively in thymic carcinomas.
Table 4 summarizes the studies that have investigated c-kit
mutations in TEMs. No kit mutations were reported in thy-
momas among 88 cases sequenced. In thymic carcinoma,
only five mutations have been described in 59 cases studied
(9%). However, this includes also case reports of two patients
who responded to c-kit tyrosine kinase inhibitors.17,18
In 2004, Strobel et al.17 reported a V560del mutation of
kit in a case of metastatic poorly differentiated epidermoid
carcinoma. This patient experienced a response to treatment
with imatinib that lasted 6 months. In 2009, Bisagni et al.
reported a case of an undifferentiated thymic carcinoma
carrying mutation D820E encoded by kit exon 17. The patient
was treated with sorafenib, and the authors reported a partial
response that lasted over 15 months.18 The mutation D820E
of c-kit activation loop has been previously reported as an
acquired resistant mutation to imatinib and sunitinib treat-
ment in GISTs.32,33
FIGURE 1. A, Membrane c-kit positive staining, 40 original magnification. B, c-kit negative staining, 40 original magnifica-
tion. C, Kaplan-Meier plot for disease-related survival of patients positive or negative for c-kit expression. D, Progression-free
survival related to c-kit expression. E, Disease-related survival of thymoma and thymic carcinoma patients. F, Progression-free
survival of thymoma and thymic carcinoma patients.
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Girard et al.14 recently reported two mutations of seven
thymic carcinomas. The authors sequenced exons 10 and 14
in addition to 9, 11, 13, and 17 evaluated in previous studies.
Interestingly, one of the mutations, H697Y, was in exon 14.
H697Y showed higher sensitivity to sunitinib than imatinib in
vitro when transfected in Ba/F3 cells. These results underline
the importance to extend the analysis to regions of kit in
thymic carcinomas beyond the most frequent sites of muta-
tions in GISTs: exon 9, 11, 13, and 17.6 We sequenced kit
from exons 1 to 20 in five thymic carcinomas and three
thymomas expressing the receptor, and in five that did not
express c-kit, and failed to identify any mutations. Pan et al.7
in 2004 and Tsuchida et al.16 in 2008 sequenced these exons
in 21 and nine thymic carcinomas, respectively, reporting no
mutations. Yoh et al.15 in 2008 identified the L576P kit
mutation in exon 17 of a thymic carcinoma. This mutation
was previously described in GIST to be activating and resis-
tant to imatinib.35
In GISTs, kit mutations have been described both in
c-kit positive tumors (the majority) and in c-kit negative
tumors.10 Durable responses to imatinib were also observed
in patients with exon 11 mutation and a very low expression
of c-kit.11
Given the frequent expression of c-kit reported in thy-
mic carcinomas, and the case reports of response to imatinib,
two small phase II studies were performed with this drug. A
phase II study including five thymic carcinomas and two B3
TABLE 4. Summary of Published Reports of c-kit Expression and Mutation in TEMs
Reports Samples IHC  IHC  Mutation  Mutation  Described Mutations
Retrospective studies
Henley et al.12 Thymoma 19 1 (5%)
T. carcinoma 4 11 (73%)
Pan et al.36 Thymoma 110 0
T. carcinoma 3 19 (86%) 21
Nakagawa et al.13 Thymoma 48 2 (4%)
T. carcinoma 4 16 (80%)
Tsuchida et al.16 Thymoma 20 0
T. carcinoma 6 11 (65%) 9
Yoh et al.15 Thymoma 24 0 22
T. carcinoma 2 15 (88%) 10 1 L576P
Girard et al.14 Thymoma 33 0 38
T. carcinoma 3 3 (50%) 5 2 V560del
Phase II studies
Salter et al.27 T. carcinoma 2 9
Giaccone et al.20 Thymoma 2 0 2
T. carcinoma 1 1 1
Case reports
Strobel et al.17 T carcinoma 1 1 V560del
Bisagni et al.18 T. carcinoma 1 1 D820E
Li et al37 T. carcinoma 1
Vasamiliette et al.28 T. carcinoma 1
Our series Thymoma 103 4 (4%) 5
T. carcinoma 7 6 (46%) 8
Total Thymoma 359 7 (2%) 67 0
Thymic carcinoma 32 95 (75%) 54 5
IHC, immunohistochemistry; TEM, thymic epithelial malignancy.
TABLE 3. Thymic Carcinoma and Thymoma Histology,
Mutation, and c-kit Immunohistochemistry
Sample Histotype c-kit IHC
kit
Mutation
I-Thy 1 Squamous cell carcinoma 3 No
I-Thy 2 Mucinous adenocarcinoma 0 No
I-Thy 3 Squamous cell carcinoma 2 —
I-Thy 4 Mucoepidermoid carcinoma 0 No
I-Thy 5 Squamous cell carcinoma 0 No
I-Thy 6 Neuroendocrine carcinoma 0 —
I-Thy 7 Squamous cell carcinoma 1 —
I-Thy 8 Squamous cell carcinoma 3 No
I-Thy 9 Squamous cell carcinoma 2 No
I-Thy 10 Neuroendocrine carcinoma 0 No
I-Thy 11 Mucinous adenocarcinoma 3 No
I-Thy 12 Undifferentiated carcinoma 0 —
I-Thy 13 Undifferentiated carcinoma 0 —
I-Thy14 Thymoma type A 1 No
I-Thy 15 Thymoma type B3 0 No
I-Thy 16 Thymoma type AB 1 No
I-Thy 17 Thymoma type A 1 No
I-Thy 18 Thymoma type B3 0 No
T-1889 Undifferentiated carcinoma cell line 025 No
IHC, immunohistochemistry.
Petrini et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1452
thymomas did not show any activity of this agent.20 Salter et
al.21 reported a series of 11 thymic carcinomas treated with
imatinib where only three obtained a stable disease as best
response. Unfortunately, only one patient with thymic carci-
noma was sequenced in these studies.
Strengths of this study are represented by the large
samples size and by the prognostic implication of c-kit
expression, reported for the first time in TEM. On the other
hand, the relative small number of c-kit-positive thymic
carcinomas sequenced and the great difference in the number
of samples that were c-kit positive versus negative have made
the difference in survival less impressive.
TEMs are rare tumors, and thymic carcinoma repre-
sents approximately only 10 to 20% of them.22 Because of the
rarity of thymic carcinomas and that responses have only
been described in case reports, and the frequency of reported
mutations is probably less than 10% in thymic carcinomas,
this represents only approximately five cases potentially di-
agnosed in the United States every year. This would make a
phase II study in thymic carcinomas with c-kit mutations very
difficult to accrue.
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